The Effect of Ketamine on Interleukin-6 Synthesis in Hepatic Resections Requiring Temporary Porto-arterial Occlusion
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00978757 |
Recruitment Status :
Completed
First Posted : September 17, 2009
Results First Posted : January 18, 2010
Last Update Posted : January 15, 2019
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Hepatectomy | Drug: Ketamine Other: Placebo | Phase 4 |

Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 42 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Treatment |
Official Title: | Phase 4: Study of Ketamine Inhibition of Interleukin 6 in Hepatic Resections Requiring Temporary Porto-arterial Occlusion |
Study Start Date : | June 2001 |
Actual Primary Completion Date : | June 2008 |
Actual Study Completion Date : | June 2008 |

Arm | Intervention/treatment |
---|---|
Experimental: Ketamine
Ketamine: 0.25 mg/kg, intravenously, one dose.
|
Drug: Ketamine
Ketamine: 0.25 mg/kg, intravenously, one dose.
Other Name: Ketamine commercially available - FADA Pharma |
Placebo Comparator: Placebo
Placebo: saline solution
|
Other: Placebo
saline solution
Other Name: Normal saline |
- The Effect of Ketamine on Interleukin 6 (IL-6) Synthesis in Hepatic Resections Requiring Temporary Porto-arterial Occlusion (Pringle Maneuver) [ Time Frame: Plasma concentration of IL-6 levels were obtained prior to surgery, upon placement of the first intravenous ]As an outcome, Interleukin 6 (IL-6) was measured in plasma concentration of hepatic resections requiring temporary porto-arterial occlusion patients.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 21 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age: 21 or older
- Planned liver resection with Pringle maneuver lasting 30-60 minutes
Exclusion Criteria:
- Chronic illness requiring corticosteroids
- Cirrhosis
- Hemodynamic instability prior to surgery
- Diabetes
- Sepsis
- Surgical interventions or chemotherapy treatments within the past 30 days
- Pregnancy
- Illnesses that could potentially affect the hepatic circulation
- Arterial hypertension
- Ocular hypertension
- Allergy to ketamine
- Preoperative portal embolization
- Radiofrequency ablation
- Patients requiring emergency surgeries

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00978757
Argentina | |
Hospital Italiano de Buenos Aires | |
Ciudad Autonoma de Buenos Aires, Argentina, 1181 |
Principal Investigator: | Francisco C Bonofiglio, MD PhD | Hospital Italiano of Buenos Aires, Argentina |
Responsible Party: | FRANCISCO CARLOS BONOFIGLIO, Anesthesiologist, Hospital Italiano de Buenos Aires |
ClinicalTrials.gov Identifier: | NCT00978757 |
Other Study ID Numbers: |
IRB#556 |
First Posted: | September 17, 2009 Key Record Dates |
Results First Posted: | January 18, 2010 |
Last Update Posted: | January 15, 2019 |
Last Verified: | March 2018 |
hepatectomy IL 6 organ failure ketamine Pringle |
Ketamine Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Anesthetics, Dissociative Anesthetics, Intravenous |
Anesthetics, General Anesthetics Central Nervous System Depressants Excitatory Amino Acid Antagonists Excitatory Amino Acid Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action |